Isozyme-selective translocation inhibitors demonstrate that epsilonPKC translocation is required for the regulation of cardiomyocyte contraction.
No takes yet. Share an insight, caveat, or question.
No clinical application yet; leaves open epsilonPKC as a selective target pending human studies.
Johnson et al. (1996) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: